ISPOR Bernie O’Brien New
Investigator Award Recipients
Jalpa A. Doshi PhD is an Assistant Professor of Medicine at the University Of Pennsylvania School Of Medicine. She is also Director of Value-Based Insurance Design Initiatives at the Leonard Davis Institute of Health Economics Center for Health Incentives and Director of the Economic Evaluations Unit of the Center for Evidence-based Practice at the University of Pennsylvania Health System. Dr. Doshi’s research interests involve economic and outcomes assessments of medication use and adherence in vulnerable patient populations such as the elderly, disabled, and chronically ill using observational as well as randomized trial data. Her work also examines prescription benefit designs and reimbursement policies and their impact on access to prescription drugs and biologics, and the quality and cost of health care. She has extensive experience conducting evaluations using Medicare (Part D), Medicaid, VA, and commercial insurance datasets in diverse disease areas such as cardiovascular and metabolic diseases, mental illnesses, rheumatoid arthritis and other inflammatory disorders. Dr. Doshi’s research also focuses on methodological issues in cost-effectiveness analysis, and she has co-authored a book on Economic Evaluation in Clinical Trials (Oxford University Press). She teaches methodology courses and workshops on cost-effectiveness analyses in randomized trials, analytic techniques to estimate cost data, and statistical methods for dealing with confounding at ISPOR and several other scientific meetings. Dr. Doshi is currently Chair of the ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Task Force and Co-chair of the Health Technology Assessment (HTA) Principles Working Group of the ISPOR HTA Special Interest Group.
Anirban Basu (MS Biostatistics, UNC, Chapel Hill; PhD, Public Policy, University of Chicago) is an Assistant Professor of Medicine at the University of Chicago and is affiliated with the Chicago Center for Health and the Social Sciences and the University of Chicago Cancer Research Foundation. He is also a faculty research fellow at the National Bureau of Economic Research. Dr. Basu’s research interests lie in revealing heterogeneity in clinical and economic outcomes in order to establish the value of individualized care and translating such information for public policy using innovative methods in comparative effectiveness and cost-effectiveness research. Dr. Basu has extensive experience in modeling health expenditure data and has also worked on the theoretical and empirical foundations in cost-effectiveness analyses and value of information analyses in the context of prostate cancer and schizophrenia. Some of his work include establishing the value of individualized care based on patient preferences, measuring the effect of patients’ health on the quality of life of their partners, estimating the future value of research in Duchenne muscular dystrophy, developing simulation models for evaluating the cost-effectiveness of pharmacological treatment algorithms in schizophrenia, and comparative effectiveness research on the dynamic intensification of glucose lowering therapies in diabetes. Dr. Basu is an Associate Editor for both Health Economics and the Journal of Health Economics and co-teaches courses on decision analysis and cost-effectiveness analysis at the University of Chicago. Dr. Basu was the recipient of the 2007 ISPOR ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research.
Patrick W. Sullivan PhD is an Assistant Professor at the University of Colorado Denver in the Pharmaceutical Outcomes Research Program. He received his PhD in Pharmaceutical Economics and Policy from the University of Southern California in 2001. Before joining USC, Dr. Sullivan worked for Merck & Co. from 1993 to 1998 and received his MA in Economics from the University of Colorado Denver in 1993. He has published widely on cost-effectiveness analysis, utility and preferences, pharmacoeconomics and patient reported outcomes. Dr. Sullivan recently completed an NIH/National Institute of Aging grant to develop a catalogue of utility scores for chronic conditions that can be used in cost-effectiveness analyses, resulting in a web-based utility calculator for chronic conditions, comorbidities and sociodemographic characteristics. In addition, Dr. Sullivan is active in teaching pharmacoeconomics and outcomes research to professional and graduate students.
Todd A. Lee, PharmD, PhD is currently a senior investigator in the Center for the Management of Complex Chronic Care (CMC3) at the Hines VA Hospital, which is one of 15 VA Centers of Excellence for health services research. He is also a research assistant professor in the Institute for Healthcare Studies and the Division of General Internal Medicine in the Northwestern University Feinberg School of Medicine. Dr. Lee’s research focuses on patient outcomes related to the use of medications with interest in both safety related issues (pharmacoepidemiology) and costs associated with medication use (pharmacoeconomics) and the intersection of the two disciplines. He has conducted both observational and interventional projects across a variety of areas including COPD, asthma, diabetes, cancer, and mental illness with particular interest in understanding the impact of the co-occurrence of multiple chronic conditions. Dr. Lee earned his PharmD from Drake University and his Ph.D. from the Pharmaceutical Outcomes Research and Policy Program at the University of Washington.
Dr. John F P Bridges, is
currently Group Leader, International Health Economics
and Outcomes Research, University of Heidelberg –School
of Medicine. Born and educated in Australia, John has
spent his professional career in North America and
Europe. In 2002 he graduated from the City University of
New York, where he studied Health Economics under
Professor Michael Grossman. In July 2002 he was
appointed Assistant Professor in Health Services
Research at Case Western Reserve University School of
Medicine, Cleveland, USA. In July 2004 he moved to the
University of Heidelberg to head a group of young
researchers in “International Health Economics and
Outcomes Research”. In July 2006, Dr. Bridges will join
the faculty at Johns Hopkins Bloomberg School of Public
Health, where he will continue his research and
international collaborations in outcomes research. Dr.
Bridges’ research is concentrated in four key areas.
First, he has argued strongly for the inclusion of
patient preferences (rather than utilities) in outcomes
research and health technology assessment (HTA). Second
he has studied the role that risk and uncertainty should
play in decision making (including Cost-Effectiveness
Analysis), using methods from finance theory such as
portfolio analysis to demonstrate how risk could be
measured and managed. Third, he has been concerned with
the effects of HTA on innovation, especially given that
some countries use HTA to delay market access. And
fourth, he has applied econometric theory to the risk
adjustment of adverse events with specific attention on
the effects that organization and team characteristics
have on the quality of care. Dr. Bridges is an active
member of ISPOR and has made numerous presentations and
presented posters at both the international and European
meetings. He also serves on the editorial boards of
PharmacoEconomics and Applied Health Economics and
Health Policy.
Shelby D. Reed, Ph.D.,
RPh, is currently
an Assistant Research Professor in the School of
Medicine at Duke University in Durham, NC. Since 2000
Dr. Reed has been a faculty member in the Center for
Clinical and Genetic Economics at the Duke Clinical
Research Institute. Dr. Reed has a broad range of
experience in planning and conducting economic and
health outcome evaluations of pharmaceuticals and health
care services across many different therapeutic areas
including infectious diseases, oncology, dermatology,
cardiovascular disease, and cerebrovascular disease.
Her methodological interests include handling and
representing uncertainty in economic evaluations,
hierarchical modeling, and conducting and assessing the
generalizability of economic evaluations performed
alongside multinational clinical trials. Dr. Reed
received her B.S. and Ph.D. from the University of
Maryland School of Pharmacy and completed a two-year NIH
post-doctoral fellowship at the University of
Washington’s Pharmaceutical Outcomes Research and Policy
Program and the Center for AIDS and STDs.
Jalpa A. Doshi PhD is an Assistant Professor of Medicine at the University Of Pennsylvania School Of Medicine. She is also Director of Value-Based Insurance Design Initiatives at the Leonard Davis Institute of Health Economics Center for Health Incentives and Director of the Economic Evaluations Unit of the Center for Evidence-based Practice at the University of Pennsylvania Health System. Dr. Doshi’s research interests involve economic and outcomes assessments of medication use and adherence in vulnerable patient populations such as the elderly, disabled, and chronically ill using observational as well as randomized trial data. Her work also examines prescription benefit designs and reimbursement policies and their impact on access to prescription drugs and biologics, and the quality and cost of health care. She has extensive experience conducting evaluations using Medicare (Part D), Medicaid, VA, and commercial insurance datasets in diverse disease areas such as cardiovascular and metabolic diseases, mental illnesses, rheumatoid arthritis and other inflammatory disorders. Dr. Doshi’s research also focuses on methodological issues in cost-effectiveness analysis, and she has co-authored a book on Economic Evaluation in Clinical Trials (Oxford University Press). She teaches methodology courses and workshops on cost-effectiveness analyses in randomized trials, analytic techniques to estimate cost data, and statistical methods for dealing with confounding at ISPOR and several other scientific meetings. Dr. Doshi is currently Chair of the ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Task Force and Co-chair of the Health Technology Assessment (HTA) Principles Working Group of the ISPOR HTA Special Interest Group.
Anirban Basu (MS Biostatistics, UNC, Chapel Hill; PhD, Public Policy, University of Chicago) is an Assistant Professor of Medicine at the University of Chicago and is affiliated with the Chicago Center for Health and the Social Sciences and the University of Chicago Cancer Research Foundation. He is also a faculty research fellow at the National Bureau of Economic Research. Dr. Basu’s research interests lie in revealing heterogeneity in clinical and economic outcomes in order to establish the value of individualized care and translating such information for public policy using innovative methods in comparative effectiveness and cost-effectiveness research. Dr. Basu has extensive experience in modeling health expenditure data and has also worked on the theoretical and empirical foundations in cost-effectiveness analyses and value of information analyses in the context of prostate cancer and schizophrenia. Some of his work include establishing the value of individualized care based on patient preferences, measuring the effect of patients’ health on the quality of life of their partners, estimating the future value of research in Duchenne muscular dystrophy, developing simulation models for evaluating the cost-effectiveness of pharmacological treatment algorithms in schizophrenia, and comparative effectiveness research on the dynamic intensification of glucose lowering therapies in diabetes. Dr. Basu is an Associate Editor for both Health Economics and the Journal of Health Economics and co-teaches courses on decision analysis and cost-effectiveness analysis at the University of Chicago. Dr. Basu was the recipient of the 2007 ISPOR ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research.
Patrick W. Sullivan PhD is an Assistant Professor at the University of Colorado Denver in the Pharmaceutical Outcomes Research Program. He received his PhD in Pharmaceutical Economics and Policy from the University of Southern California in 2001. Before joining USC, Dr. Sullivan worked for Merck & Co. from 1993 to 1998 and received his MA in Economics from the University of Colorado Denver in 1993. He has published widely on cost-effectiveness analysis, utility and preferences, pharmacoeconomics and patient reported outcomes. Dr. Sullivan recently completed an NIH/National Institute of Aging grant to develop a catalogue of utility scores for chronic conditions that can be used in cost-effectiveness analyses, resulting in a web-based utility calculator for chronic conditions, comorbidities and sociodemographic characteristics. In addition, Dr. Sullivan is active in teaching pharmacoeconomics and outcomes research to professional and graduate students.
Todd A. Lee, PharmD, PhD is currently a senior investigator in the Center for the Management of Complex Chronic Care (CMC3) at the Hines VA Hospital, which is one of 15 VA Centers of Excellence for health services research. He is also a research assistant professor in the Institute for Healthcare Studies and the Division of General Internal Medicine in the Northwestern University Feinberg School of Medicine. Dr. Lee’s research focuses on patient outcomes related to the use of medications with interest in both safety related issues (pharmacoepidemiology) and costs associated with medication use (pharmacoeconomics) and the intersection of the two disciplines. He has conducted both observational and interventional projects across a variety of areas including COPD, asthma, diabetes, cancer, and mental illness with particular interest in understanding the impact of the co-occurrence of multiple chronic conditions. Dr. Lee earned his PharmD from Drake University and his Ph.D. from the Pharmaceutical Outcomes Research and Policy Program at the University of Washington.
Dr. John F P Bridges, is
currently Group Leader, International Health Economics
and Outcomes Research, University of Heidelberg –School
of Medicine. Born and educated in Australia, John has
spent his professional career in North America and
Europe. In 2002 he graduated from the City University of
New York, where he studied Health Economics under
Professor Michael Grossman. In July 2002 he was
appointed Assistant Professor in Health Services
Research at Case Western Reserve University School of
Medicine, Cleveland, USA. In July 2004 he moved to the
University of Heidelberg to head a group of young
researchers in “International Health Economics and
Outcomes Research”. In July 2006, Dr. Bridges will join
the faculty at Johns Hopkins Bloomberg School of Public
Health, where he will continue his research and
international collaborations in outcomes research. Dr.
Bridges’ research is concentrated in four key areas.
First, he has argued strongly for the inclusion of
patient preferences (rather than utilities) in outcomes
research and health technology assessment (HTA). Second
he has studied the role that risk and uncertainty should
play in decision making (including Cost-Effectiveness
Analysis), using methods from finance theory such as
portfolio analysis to demonstrate how risk could be
measured and managed. Third, he has been concerned with
the effects of HTA on innovation, especially given that
some countries use HTA to delay market access. And
fourth, he has applied econometric theory to the risk
adjustment of adverse events with specific attention on
the effects that organization and team characteristics
have on the quality of care. Dr. Bridges is an active
member of ISPOR and has made numerous presentations and
presented posters at both the international and European
meetings. He also serves on the editorial boards of
PharmacoEconomics and Applied Health Economics and
Health Policy. 
Shelby D. Reed, Ph.D.,
RPh, is currently
an Assistant Research Professor in the School of
Medicine at Duke University in Durham, NC. Since 2000
Dr. Reed has been a faculty member in the Center for
Clinical and Genetic Economics at the Duke Clinical
Research Institute. Dr. Reed has a broad range of
experience in planning and conducting economic and
health outcome evaluations of pharmaceuticals and health
care services across many different therapeutic areas
including infectious diseases, oncology, dermatology,
cardiovascular disease, and cerebrovascular disease.
Her methodological interests include handling and
representing uncertainty in economic evaluations,
hierarchical modeling, and conducting and assessing the
generalizability of economic evaluations performed
alongside multinational clinical trials. Dr. Reed
received her B.S. and Ph.D. from the University of
Maryland School of Pharmacy and completed a two-year NIH
post-doctoral fellowship at the University of
Washington’s Pharmaceutical Outcomes Research and Policy
Program and the Center for AIDS and STDs.